Aurobindo Pharma Ltd

Net profit of Aurobindo Pharma rose 7.62% to Rs 910.29 crore in the quarter ended December 2025 as against Rs 845.81 crore during the previous quarter ended December 2024. Sales rose 9.01% to Rs 8604.51 crore in the quarter ended December 2025 as against Rs 7893.15 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales8604.517893.15 9 OPM %20.6119.99 - PBDT1868.581618.38 15 PBT1403.851199.85 17 NP910.29845.81 8 Powered by Capital Market - Live

The board of Aurobindo Pharma at its meeting held on 09 February 2026 has approved a proposal to file a scheme of amalgamation for merger of Auro Vaccines, a wholly owned step-down subsidiary of the Company with Curateq Biologics, a wholly owned subsidiary of the Company, with Hon'ble NCLT, Hyderabad. Powered by Capital Market - Live

The board of Aurobindo Pharma at its meeting held on 09 February 2026 has approved to enter into a power purchase agreement with Garuda Renewables, to procure renewable energy from hybrid sources of wind and solar and in this connection the Company will be investing Rs. 66 crores for acquiring upto 26% stake in Garuda Renewables. Powered by Capital Market - Live

The board of Aurobindo Pharma at its meeting held on 09 February 2026 has approved the appointment of Dr. Punita Kumar Sinha (DIN: 05229262) as Additional Director designated as Non-Executive Independent Director for a term of 3 (Three) years with effect from 09 February 2026. Powered by Capital Market - Live

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, 502307, Telangana, from 27 January to 06 February 2026. The inspection concluded with 11 observations. The observations are procedural in nature and will be responded to within the stipulated time. Powered by Capital Market - Live

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1187.9, up 3.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 25293. The Sensex is at 82170.1, down 0.48%. Aurobindo Pharma Ltd has gained around 0.41% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 4.67% in last one month and is currently quoting at 21564, up 0.46% on the day. The volume in the stock stood at 49.13 lakh shares today, compared to the daily average of 8.28 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 1187.9, up 3.04% on the day. Aurobindo Pharma Ltd is up 1.37% in last one year as compared to a 7.59% jump in NIFTY and a 1.05% jump in the Nifty Pharma index.The PE of the stock is 33.07 based on TTM earnings ending September 25.Powered by Capital Market - Live

Ramkrishna Forgings Ltd, Leela Palaces Hotels & Resorts Ltd, Narayana Hrudayalaya Ltd, Craftsman Automation Ltd are among the other stocks to see a surge in volumes on BSE today, 30 January 2026.Aurobindo Pharma Ltd clocked volume of 5.81 lakh shares by 10:46 IST on BSE, a 53.98 times surge over two-week average daily volume of 10754 shares. The stock gained 2.13% to Rs.1,175.00. Volumes stood at 13339 shares in the last session.Ramkrishna Forgings Ltd notched up volume of 4.2 lakh shares by 10:46 IST on BSE, a 28.34 fold spurt over two-week average daily volume of 14831 shares. The stock rose 2.07% to Rs.518.10. Volumes stood at 6978 shares in the last session.Leela Palaces Hotels & Resorts Ltd witnessed volume of 14.11 lakh shares by 10:46 IST on BSE, a 27.8 times surge over two-week average daily volume of 50757 shares. The stock increased 1.29% to Rs.406.75. Volumes stood at 3.08 lakh shares in the last session.Narayana Hrudayalaya Ltd registered volume of 2.13 lakh shares by 10:46 IST on BSE, a 9.06 fold spurt over two-week average daily volume of 23486 shares. The stock rose 1.79% to Rs.1,774.30. Volumes stood at 9677 shares in the last session.Craftsman Automation Ltd registered volume of 21129 shares by 10:46 IST on BSE, a 8.13 fold spurt over two-week average daily volume of 2598 shares. The stock rose 0.55% to Rs.7,348.45. Volumes stood at 2893 shares in the last session.Powered by Capital Market - Live

Khandelwal Laboratories operates in India's pharmaceutical industry with a presence in both oncology and non-oncology branded formulations. The non-oncology portfolio comprises 23 brands across 67 stock-keeping units (SKUs), along with nine products in the pipeline where anti-infective as well as pain management are the major portfolios. The business generated a turnover of Rs 113.53 crore in FY2024-25 with an EBITDA of Rs 28.99 crore. The transaction was signed and completed on 1 January 2026. Under the agreement, Auro Pharma has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories as a going concern on a slump-sale basis. The acquisition includes inventory, intellectual property, employees, contracts, and other associated assets. The total cash consideration for the transaction is Rs 325 crore. The acquisition is expected to strengthen the company's pain management and anti-infective portfolio, complementing its existing offerings and supporting expansion in the domestic market. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live

Auro Pharma (Auro Pharma), a wholly owned subsidiary of Aurobindo Pharma at its meeting held today i.e. 01 January 2026 has approved the acquisition of non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis through a Business Transfer Agreement (BTA). Powered by Capital Market - Live